Federated Hermes Inc. Sells 12,208 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Federated Hermes Inc. lowered its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 4.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 262,542 shares of the specialty pharmaceutical company’s stock after selling 12,208 shares during the quarter. Federated Hermes Inc.’s holdings in ANI Pharmaceuticals were worth $9,488,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in ANIP. Investment Counselors of Maryland LLC raised its holdings in shares of ANI Pharmaceuticals by 3.6% in the 1st quarter. Investment Counselors of Maryland LLC now owns 352,014 shares of the specialty pharmaceutical company’s stock worth $12,722,000 after buying an additional 12,162 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of ANI Pharmaceuticals by 14.0% in the 1st quarter. Geode Capital Management LLC now owns 160,014 shares of the specialty pharmaceutical company’s stock worth $5,782,000 after buying an additional 19,600 shares in the last quarter. Prudential Financial Inc. raised its holdings in shares of ANI Pharmaceuticals by 60.8% in the 1st quarter. Prudential Financial Inc. now owns 67,918 shares of the specialty pharmaceutical company’s stock worth $2,455,000 after buying an additional 25,685 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of ANI Pharmaceuticals by 9.3% in the 1st quarter. JPMorgan Chase & Co. now owns 58,868 shares of the specialty pharmaceutical company’s stock worth $2,128,000 after buying an additional 5,024 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of ANI Pharmaceuticals by 0.8% in the 1st quarter. Principal Financial Group Inc. now owns 74,758 shares of the specialty pharmaceutical company’s stock worth $2,702,000 after buying an additional 607 shares in the last quarter. Institutional investors own 59.31% of the company’s stock.

ANIP has been the subject of a number of recent research reports. Zacks Investment Research cut ANI Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, May 24th. Raymond James increased their target price on ANI Pharmaceuticals from $40.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, May 10th. Finally, TheStreet raised ANI Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Friday, May 28th.

ANIP stock opened at $33.62 on Friday. The company’s fifty day simple moving average is $34.22. ANI Pharmaceuticals, Inc. has a fifty-two week low of $23.55 and a fifty-two week high of $40.00. The firm has a market cap of $415.54 million, a PE ratio of 11.22 and a beta of 1.28. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.21 and a quick ratio of 1.48.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Thursday, May 6th. The specialty pharmaceutical company reported $1.04 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.71 by $0.33. ANI Pharmaceuticals had a positive return on equity of 17.92% and a negative net margin of 7.25%. The firm had revenue of $54.52 million during the quarter, compared to analysts’ expectations of $48.00 million. As a group, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 2.72 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Recommended Story: What impact do institutional investors have on markets?

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.